| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pharmacology 1, Nagasaki University School of Medicine, Nagasaki, Japan;
Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Tokyo, Japan; and
Autoimmune Disease Unit, Cedars-Sinai Research Institute and School of Medicine, University of California, Los Angeles, CA 90048
Graves’ hyperthyroidism has long been considered to be a Th2-type autoimmune disease because it is directly mediated by autoantibodies against the thyrotropin receptor (TSHR). However, several lines of evidence have recently challenged this concept. The present study evaluated the Th1/Th2 paradigm in Graves’ disease using a recently established murine model involving injection of adenovirus expressing the TSHR (AdCMVTSHR). Coinjection with adenovirus expressing IL-4 (AdRGDCMVIL-4) decreased the ratio of Th1/Th2-type anti-TSHR Ab subclasses (IgG2a/IgG1) and suppressed the production of IFN-
by splenocytes in response to TSHR Ag. Importantly, immune deviation toward Th2 was accompanied by significant inhibition of thyroid-stimulating Ab production and reduction in hyperthyroidism. However, in a therapeutic setting, injection of AdRGDCMVIL-4 alone or in combination with AdCMVTSHR into hyperthyroid mice had no beneficial effect. In contrast, coinjection of adenoviruses expressing IL-12 and the TSHR promoted the differentiation of Th1-type anti-TSHR immune responses as demonstrated by augmented Ag-specific IFN- secretion from splenocytes without changing disease incidence. Coinjection of adenoviral vectors expressing IL-4 or IL-12 had no effect on the titers of anti-TSHR Abs determined by ELISA or thyroid-stimulating hormone-binding inhibiting Ig assays, suggesting that Ab quality, not quantity, is responsible for disease induction. Our observations demonstrate the critical role of Th1 immune responses in a murine model of Graves’ hyperthyroidism. These data may raise a cautionary note for therapeutic strategies aimed at reversing Th2-mediated autoimmune responses in Graves’ disease in humans.
This article has been cited by other articles:
|
|
 |
|
  A. V. Misharin, Y. Nagayama, H. A. Aliesky, Y. Mizutori, B. Rapoport, and S. M. McLachlan Attenuation of Induced Hyperthyroidism in Mice by Pretreatment with Thyrotropin Receptor Protein: Deviation of Thyroid-Stimulating to Nonfunctional Antibodies Endocrinology, August 1, 2009; 150(8): 3944 - 3952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakahara, Y. Nagayama, O. Saitoh, R. Sogawa, S. Tone, and N. Abiru Expression of Immunoregulatory Molecules by Thyrocytes Protects Nonobese Diabetic-H2h4 Mice from Developing Autoimmune Thyroiditis Endocrinology, March 1, 2009; 150(3): 1545 - 1551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takahashi, M. Amagai, T. Nishikawa, Y. Fujii, Y. Kawakami, and M. Kuwana Novel System Evaluating In Vivo Pathogenicity of Desmoglein 3-Reactive T Cell Clones Using Murine Pemphigus Vulgaris J. Immunol., July 15, 2008; 181(2): 1526 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Saitoh, N. Abiru, M. Nakahara, and Y. Nagayama CD8+CD122+ T Cells, a Newly Identified Regulatory T Subset, Negatively Regulate Graves' Hyperthyroidism in a Murine Model Endocrinology, December 1, 2007; 148(12): 6040 - 6046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Inukai, A. Momobayashi, N. Sugawara, and Y. Aso Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease Eur. J. Endocrinol., June 1, 2007; 156(6): 623 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kaneda, A. Honda, A. Hakozaki, T. Fuse, A. Muto, and T. Yoshida An Improved Graves' Disease Model Established by Using in Vivo Electroporation Exhibited Long-Term Immunity to Hyperthyroidism in BALB/c Mice Endocrinology, May 1, 2007; 148(5): 2335 - 2344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Gilbert, S. L. Kalled, J. Moorhead, D. M. Hess, P. Rennert, Z. Li, M. Z. Khan, and J. P. Banga Treatment of Autoimmune Hyperthyroidism in a Murine Model of Graves' Disease with Tumor Necrosis Factor-Family Ligand Inhibitors Suggests a Key Role for B Cell Activating Factor in Disease Pathology Endocrinology, October 1, 2006; 147(10): 4561 - 4568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Saitoh and Y. Nagayama Regulation of Graves' Hyperthyroidism with Naturally Occurring CD4+CD25+ Regulatory T Cells in a Mouse Model Endocrinology, May 1, 2006; 147(5): 2417 - 2422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. McLachlan, Y. Nagayama, and B. Rapoport Insight into Graves' Hyperthyroidism from Animal Models Endocr. Rev., October 1, 2005; 26(6): 800 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Aust, M Kamprad, P Lamesch, and E Schmucking CXCR6 within T-helper (Th) and T-cytotoxic (Tc) type 1 lymphocytes in Graves' disease (GD) Eur. J. Endocrinol., April 1, 2005; 152(4): 635 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. McLachlan, H. Braley-Mullen, C.-R. Chen, H. Aliesky, P. N. Pichurin, and B. Rapoport Dissociation between Iodide-Induced Thyroiditis and Antibody-Mediated Hyperthyroidism in NOD.H-2h4 Mice Endocrinology, January 1, 2005; 146(1): 294 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Chen, H. Aliesky, P. N. Pichurin, Y. Nagayama, S. M. McLachlan, and B. Rapoport Susceptibility Rather than Resistance to Hyperthyroidism Is Dominant in a Thyrotropin Receptor Adenovirus-Induced Animal Model of Graves' Disease as Revealed by BALB/c-C57BL/6 Hybrid Mice Endocrinology, November 1, 2004; 145(11): 4927 - 4933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nagayama, S. M. McLachlan, B. Rapoport, and K. Oishi Graves' Hyperthyroidism and the Hygiene Hypothesis in a Mouse Model Endocrinology, November 1, 2004; 145(11): 5075 - 5079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Land, J. S. Moll, M. H. Kaplan, and G. S. Seetharamaiah Signal Transducer and Activator of Transcription (Stat)-6-Dependent, But Not Stat4-Dependent, Immunity Is Required for the Development of Autoimmunity in Graves' Hyperthyroidism Endocrinology, August 1, 2004; 145(8): 3724 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nagayama, K. Watanabe, M. Niwa, S. M. McLachlan, and B. Rapoport Schistosoma mansoni and {alpha}-Galactosylceramide: Prophylactic Effect of Th1 Immune Suppression in a Mouse Model of Graves' Hyperthyroidism J. Immunol., August 1, 2004; 173(3): 2167 - 2173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Chen, P. Pichurin, G. D. Chazenbalk, H. Aliesky, Y. Nagayama, S. M. McLachlan, and B. Rapoport Low-Dose Immunization with Adenovirus Expressing the Thyroid-Stimulating Hormone Receptor A-Subunit Deviates the Antibody Response toward That of Autoantibodies in Human Graves' Disease Endocrinology, January 1, 2004; 145(1): 228 - 233. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
